Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gracell Biotechnologies Inc ADR (NQ: GRCL )

2.800 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,803
Open 2.800
Bid (Size) 2.800 (11)
Ask (Size) 2.980 (2)
Prev. Close 2.800
Today's Range 2.800 - 2.800
52wk Range 1.400 - 5.691
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop... 
Via Talk Markets

Performance

YTD
+29.63%
+29.63%
1 Month
+52.17%
+52.17%
3 Month
+36.59%
+36.59%
6 Month
-11.67%
-11.67%
1 Year
-14.89%
-14.89%

More News

Read More
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies's Earnings: A Preview
Via Benzinga
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
Via Talk Markets
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Gracell Biotech's Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims
Via Benzinga
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022
Via Benzinga
Gracell Biotechnologies: Q2 Earnings Insights
Via Benzinga
Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.